Some preclinical data suggest that inhibition of EZH2 may be effective in ovarian cancer, and mechanistically, inhibition of EZH2 histone methyltransferase activity is synthetically lethal in ARID1A mutant cancers (87, 88). Here, EZH2 is linked to ovarian carcinoma.